Abstract
The phytochemical profiling of different extracts revealed the presence of high concentration of CBD in 80:20 hydroalcoholic extract, and that of THC in 60:40 hydroalcoholic extract. The MTT assay of combination of CBD and THC highlighted the extracts as potent cytotoxic agents against prostate cancer (PC3) cells, with IC50 values of 1292 ng/ml, 953.3 ng/ml and 1134 ng/ml, respectively for HCP-CO4, HCM-CO1 & HCZ-CO1. The molecular docking study revealed a good binding of androgen receptor (PDB ID, 2am9) with CBD and THC possessing binding affinity energy of -7.1 and -7.2 kcal/mol respectively. Based on the amino acid residual interaction of CBD and THC within the 2am9 receptor, THC reported additional hydrogen bonds as compared to CBD, suggesting it to be more potent antagonist in comparison to CBD. The present study highlighted the potential of CBD and THC as a therapeutic agent for treatment of prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
